Anti-CD4 antibody and dendrimeric peptide based targeted nano-liposomal dual drug formulation for the treatment of HIV infection

• DOI: 10.1016/j.lfs.2023.122226
• Publication Date: 2023-11-02T13:54:07Z
• Authors: Sadhana P. Mutalik; Shraddha Y. Gaikwad; Gasper Fernandes; Ashwini More; Sanjay Kulkarni; Shaik Mohammad Ab...; Karnaker Tupally; Harendra S. Parekh; Smita Kulkarni; Anupam Mukherjee; Srinivas Mutalik
• Keywords: Targeted drug delivery

Development and characterization of LAM DTG loaded liposomes conjugated anti-CD4 antibody peptide dendrimer (PD2) to improve the therapeutic efficacy achieve targeted treatment for HIV infection. A 2-level full factorial design was used optimize preparation dual drug liposomes. Optimized ligand were assessed their cytotoxicity cell internalization on TZM-bl cells. Anti-HIV efficiency screened inhibitory potential in cells activities confirmed using Peripheral Blood Mononuclear Cells (PBMCs). The particle size optimized drug-loaded 133.7 ± 4.04 nm, spherical morphology by TEM analysis. entrapment 34 4.9 % 54 1.8 DTG, respectively, a slower vitro release observed when entrapped into similar free solutions. Conjugation PD2 did not significantly influence but it enhanced uptake Conjugated exhibited better inhibition with lower IC50 values (0.0003 0.0002 μg/mL) compared solutions (0.002 0.001 μg/mL). liposomal formulations have shown both screening confirmatory cell-based assays. results demonstrated targeting ability dendrimer. also improved anti-HIV DTG.